Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
NeoTYPE® Cholangiocarcinoma Profile
- Next Generation Sequencing (NGS)
The NeoTYPE Cholangiocarcinoma Profile analyzes 19 biomarkers through a combination of next-generation sequencing (NGS), FISH, and IHC as listed below. Test orders include summary interpretation of all results to help guide treatment decisions. A microsatellite instability (MSI) NGS result of "indeterminate" will create a reflex to MSI by PCR as long as the tumor percentage is ≥40% and paired normal tissue is available. NGS (15 genes + 2 biomarkers): APC, ARID1A, BAP1, BRAF, EGFR, ERBB2, HRAS, IDH1, IDH2, KRAS, MET (c-MET), NRAS, PBRM1, SMAD4, TP53, plus Microsatellite instability (MSI) and Tumor Mutation Burden (TMB). FISH (1 biomarker): FGFR2 IHC (1 biomarker): PD-L1 LDT.
Turnaround time
14 Days
Level of Service
- Global
New York Approved: Yes
Specimen Requirements
FFPE tissue: Paraffin block preferred. Please use 10% buffered formalin fixative. Do not use zinc fixatives.
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.
CPT Code(s)*
81457x1, 88360x1, 88374x1 or 88377x1
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: March 05, 2025